Current disease status-First occurrence of the leukemia - Page 7 of 12 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the leukemia Posts on Medivizor

Congestive heart failure in children with acute leukemia

Congestive heart failure in children with acute leukemia

Posted by on Sep 15, 2018 in Leukemia | 0 comments

In a nutshell This study identified the risks and incidence of congestive heart failure in children with acute leukemia (ALL or AML). The study found that risks of heart failure with ALL or AML included female gender and diagnosis at a younger age. Some background Congestive heart failure (CHF) is a condition in which the heart is unable to pump blood...

Read More

Can T-cell therapy treat unresponsive ALL?

Can T-cell therapy treat unresponsive ALL?

Posted by on Sep 13, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the current evidence for the effect of changing genes in T-cells (a type of immune cell) to target cancer cells in acute lymphoblastic leukemia (ALL). The study found that these T-cells were safe and effective in the treatment of ALL. Some background Acute Lymphoblastic Leukemia is a type of bone marrow cancer...

Read More

Comparing chemoimmunotherapy and ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Sep 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of patients with chronic lymphocytic leukemia who received chemoimmunotherapy or ibrutinib. This study suggested that ibrutinib may have more favorable outcomes for these patients when compared to chemoimmunotherapy. Some background Chemoimmunotherapy (CIT) is a treatment option that can be used...

Read More

Is a low-intensity chemotherapy treatment plan safe and effective for elderly patients with Acute Myeloid Leukemia?

Posted by on Sep 6, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to create a safe and effective low-intensity chemotherapy treatment plan for elderly patients with AML . This is an ongoing clinical trial and so far the authors have found the therapy has been safe and effective. Some background Outcomes for elderly patients with AML in the past have not been good due to the high...

Read More

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Posted by on Aug 21, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...

Read More

Outcomes and management of CLL treated with venetoclax

Outcomes and management of CLL treated with venetoclax

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that venetoclax was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a type of cancer of the bone marrow that can lead to an abnormal immune system. Over...

Read More

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Posted by on Aug 18, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...

Read More

What major factors affect disease progression and outcome in adults with acute myeloid leukemia?

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...

Read More

Drug interactions with tyrosine kinase inhibitors in chronic myeloid leukemia

Drug interactions with tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Jul 17, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the interactions between tyrosine kinase inhibitors and other drugs taken at the same time in patients with chronic myeloid leukemia. This study concluded that drug interactions were found in a significant number of patients, with mild side effects. Some background Imatinib (Gleevec) and similar drugs are the...

Read More

A comparison of two different types of transplant therapy to treat acute myeloid leukemia

A comparison of two different types of transplant therapy to treat acute myeloid leukemia

Posted by on Jul 15, 2018 in Leukemia | 0 comments

In a nutshell This study compared two different transplant therapies used to treat acute myeloid leukaemia (AML), unmanipulated haploidentical stem cell treatment (Haplo-SCT) and HLA-matched unrelated donor stem cell transplantation (MUD). The study found that both options are useful in treating AML but MUD may have increased risk of graft versus host...

Read More